Sandro V Porceddu1, Rob Milne2, Elizabeth Brown3, Anne Bernard4, Reza Rahbari5, Bena Cartmill5, Matthew Foote6, Margaret McGrath5, Jermaine Coward6, Benedict Panizza7. 1. Department of Cancer Services, Princess Alexandra Hospital, Brisbane, Queensland, Australia; Faculty of Medicine, University of Queensland, Queensland, Australia. Electronic address: sandro.porceddu@health.qld.gov.au. 2. Faculty of Medicine, University of Queensland, Queensland, Australia. 3. Department of Cancer Services, Princess Alexandra Hospital, Brisbane, Queensland, Australia; School of Clinical Sciences, Queensland University of Technology, Australia. 4. QFAB Bioinformatics, Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia. 5. Department of Cancer Services, Princess Alexandra Hospital, Brisbane, Queensland, Australia. 6. Department of Cancer Services, Princess Alexandra Hospital, Brisbane, Queensland, Australia; Faculty of Medicine, University of Queensland, Queensland, Australia. 7. Faculty of Medicine, University of Queensland, Queensland, Australia; Department of Otolaryngology, Head and Neck Surgery, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
Abstract
OBJECTIVES: To determine whether the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S) for HPV associated oropharyngeal carcinoma (HPV+OPC) is a better discriminator of overall survival (OS), compared with the 7th edition (7th Ed) AJCC/UICC TNM staging following curative radiotherapy (RT). MATERIAL AND METHODS: The 5-year OS for all patients with non-metastatic (M0) p16-confirmed OPC treated between 2005 and 2015 was determined and grouped based on the 7th Ed AJCC/UICC TNM and ICON-S staging. RESULTS: A total of 279 patients met the inclusion criteria. The 5-year OS with the 7th Ed TNM classification were Stage I/II 88.9% (95% CI; 70.6-100%), Stage III 93.8% (95% CI; 85.9-100%), Stage IVa 86.4% (95% CI; 81.6-91.5%) and Stage IVb 62.3% (95% CI; 46.8-82.8%). On multivariate Cox regression analysis there was no statistically significant OS difference when comparing Stage I/II with, Stage III (p=0.98, HR=0.97, 95% CI; 0.11-8.64), IVa (p=0.67, HR=1.56, 95% CI; 0.2-11.94) and IVb (p=0.11, HR=5.54, 95% CI; 0.69-44.52), respectively. The 5-year OS with ICON-S staging were Stage I 93.6% (95% CI; 89.4-98.0%), Stage II 81.9% (95% CI; 73.7-91.1%) and Stage III 69.1% (95%; 57.9-82.6%). There was a consistent decrease of OS with increasing stage. On multivariate Cox regression analysis, when compared to Stage I, OS was significantly lower for stage II (p=0.007, HR=2.84, 95% CI; 1.33-6.05) and stage III (p<0.001, HR=3.78, 95% CI; 1.81-7.92), respectively. CONCLUSION: The ICON-S staging provides better OS stratification for HPV+OPC following RT compared with the 7th Ed TNM staging.
OBJECTIVES: To determine whether the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S) for HPV associated oropharyngeal carcinoma (HPV+OPC) is a better discriminator of overall survival (OS), compared with the 7th edition (7th Ed) AJCC/UICC TNM staging following curative radiotherapy (RT). MATERIAL AND METHODS: The 5-year OS for all patients with non-metastatic (M0) p16-confirmed OPC treated between 2005 and 2015 was determined and grouped based on the 7th Ed AJCC/UICC TNM and ICON-S staging. RESULTS: A total of 279 patients met the inclusion criteria. The 5-year OS with the 7th Ed TNM classification were Stage I/II 88.9% (95% CI; 70.6-100%), Stage III 93.8% (95% CI; 85.9-100%), Stage IVa 86.4% (95% CI; 81.6-91.5%) and Stage IVb 62.3% (95% CI; 46.8-82.8%). On multivariate Cox regression analysis there was no statistically significant OS difference when comparing Stage I/II with, Stage III (p=0.98, HR=0.97, 95% CI; 0.11-8.64), IVa (p=0.67, HR=1.56, 95% CI; 0.2-11.94) and IVb (p=0.11, HR=5.54, 95% CI; 0.69-44.52), respectively. The 5-year OS with ICON-S staging were Stage I 93.6% (95% CI; 89.4-98.0%), Stage II 81.9% (95% CI; 73.7-91.1%) and Stage III 69.1% (95%; 57.9-82.6%). There was a consistent decrease of OS with increasing stage. On multivariate Cox regression analysis, when compared to Stage I, OS was significantly lower for stage II (p=0.007, HR=2.84, 95% CI; 1.33-6.05) and stage III (p<0.001, HR=3.78, 95% CI; 1.81-7.92), respectively. CONCLUSION: The ICON-S staging provides better OS stratification for HPV+OPC following RT compared with the 7th Ed TNM staging.
Authors: Douglas R Farquhar; Andrew J Coniglio; Maheer M Masood; Nicholas Lenze; Paul Brennan; Devasena Anantharaman; Behnoush Abedi-Ardekani; Adam M Zanation; Mark C Weissler; Andrew F Olshan; Siddharth Sheth; Trevor G Hackman Journal: Oral Oncol Date: 2020-05-31 Impact factor: 5.337
Authors: Carole Fakhry; Qiang Zhang; Maura L Gillison; Phuc Felix Nguyen-Tân; David I Rosenthal; Randal S Weber; Louise Lambert; Andy M Trotti; William L Barrett; Wade L Thorstad; Sue S Yom; Stuart J Wong; John A Ridge; Shyam S D Rao; Sharon Spencer; Andre Fortin; David Raben; Jonathan Harris; Quynh-Thu Le Journal: Cancer Date: 2019-03-26 Impact factor: 6.860
Authors: J Chandra; W P Woo; N Finlayson; H Y Liu; M McGrath; R Ladwa; M Brauer; Y Xu; S Hanson; B Panizza; I H Frazer; Sandro V Porceddu Journal: Cancer Immunol Immunother Date: 2020-09-12 Impact factor: 6.968
Authors: Peter G Hawkins; Michelle L Mierzwa; Emily Bellile; William C Jackson; Kelly M Malloy; Steven B Chinn; Matthew E Spector; Andrew G Shuman; Chaz L Stucken; Scott A McLean; Carol R Bradford; Mark E Prince; Thomas E Carey; Francis P Worden; Paul L Swiecicki; Jeremy M G Taylor; Gregory T Wolf; Avraham Eisbruch; Keith A Casper Journal: Head Neck Date: 2019-02-18 Impact factor: 3.821
Authors: Tom Bradish; H Fisher; V Paleri; M Robinson; D Meikle; C Kelly; J O'Hara Journal: Eur Arch Otorhinolaryngol Date: 2020-07-03 Impact factor: 2.503